APA (7th ed.) Citation

N, S., C, D., S, Y., M, O., C, C., R, P., . . . JM, T. (2016). Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. Molecular medicine (Cambridge, Mass.), 22, 632. https://doi.org/10.2119/molmed.2015.00210

Chicago Style (17th ed.) Citation

N, Satake, et al. "Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate." Molecular Medicine (Cambridge, Mass.) 22 (2016): 632. https://doi.org/10.2119/molmed.2015.00210.

MLA (9th ed.) Citation

N, Satake, et al. "Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate." Molecular Medicine (Cambridge, Mass.), vol. 22, 2016, p. 632, https://doi.org/10.2119/molmed.2015.00210.